Ten-year evaluation of homogeneous low-density lipoprotein cholesterol methods developed by Japanese manufacturers
- 1 January 2010
- journal article
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 17 (12), 1275-1281
- https://doi.org/10.5551/jat.5470
Abstract
The risk index for atherosclerotic cardiovascular diseases in the Japanese metabolic syndrome-focused health checkup program was changed from total cholesterol (TC) to low-density lipoprotein cholesterol (LDL-C). We discuss the validity of this change with respect to standardization. The beta-quantification procedure of the Centers for Disease Control and Prevention (CDC) uses the LDL-C reference value as a target. Clinical laboratories and commercial manufacturers use homogeneous LDL-C methods for standardization. (A) For clinical laboratories, LDL-C in 648 samples requested from 108 hospitals was analyzed. (B) Manufacturers participated in the CDC/Cholesterol Reference Method Laboratory Network LDL-C standardization protocol. The standardization was conducted with a performance follow-up for the 10-year period from 1998 to 2008 at 2-year intervals, 6 times. (A) In clinical laboratories, acceptable LDL-C levels within ±4% of the CDC's criteria remained 70.4%, 456 of 648 subjects. Negative maximum bias deviating from the LDL-C target value was -35.8%, -52.5 mg/dL, and positive maximum bias was +24.5%, +32.3 mg/dL. (B) For manufacturers, the standardization achievement rate of the analytical reagent/instrument/calibrator system in the last four standardizations from 2002 to 2008 remained on average 66.6%, far lower than the level required. The standardization achievement rate of homogeneous LDL-C methods was much low-er than that of TC. TC should still be used as a risk index for atherosclerotic cardiovascular diseases. The standardization achievement rate of homogeneous LDL-C should be maintained at 100%, at least using samples with normal lipoprotein profiles. The accuracy and specificity of LDL-C should be further improved before practical and clinical use.Keywords
This publication has 15 references indexed in Scilit:
- Seven Direct Methods for Measuring HDL and LDL Cholesterol Compared with Ultracentrifugation Reference Measurement ProceduresClinical Chemistry, 2010
- Association between Non-High-Density Lipoprotein Cholesterol Concentrations and Mortality from Coronary Heart Disease Among Japanese Men and Women: The Ibaraki Prefectural Health StudyJournal of Atherosclerosis and Thrombosis, 2010
- Differential reactivities of four homogeneous assays for LDL-cholesterol in serum to intermediate-density lipoproteins and small dense LDL: Comparisons with the Friedewald equationClinica Chimica Acta; International Journal of Clinical Chemistry, 2009
- Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study: The Suita studyAtherosclerosis, 2009
- Low-Density Lipoprotein Cholesterol Concentrations and Death Due to Intraparenchymal HemorrhageCirculation, 2009
- Measurement Performance of Reagent Manufacturers by Centers for Disease Control and Prevention/Cholesterol Reference Method Laboratory Network Lipid Standardization Specified for Metabolic Syndrome-Focused Health Checkups Program in JapanJournal of Atherosclerosis and Thrombosis, 2009
- Evaluation of an HPLC method for LDL-cholesterol determination in patients with various lipoprotein abnormalities in comparison with beta-quantificationClinica Chimica Acta; International Journal of Clinical Chemistry, 2008
- Metabolic SyndromeJournal of Atherosclerosis and Thrombosis, 2008
- Goals of Dyslipidemia Management Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for JapaneseJournal of Atherosclerosis and Thrombosis, 2007
- Improved Specificity of a New Homogeneous Assay for LDL-Cholesterol in Serum with Abnormal LipoproteinsClinical Chemistry, 2006